Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
In a casino, if you play long enough, the House always wins; this is just a matter of probabilities and available resources. It’s different in the stock market, even though there is a tendency to refer to stock investing as a game. Smart investors don’t have to ‘beat the house’ to come out ahead; this is not a zero-sum game. Rather, it’s a game of strategy. Successful investors will look for some edge, an ‘in’ that will lead them toward winning investments. This search naturally leads some inves...
Biohaven's (BHVN) recently approved migraine drug, Nurtec ODT, continues to demonstrate strong launch uptake.
Agreement enables Biohaven to exercise option on up to three of Artizan’s candidates for the treatment of inflammatory bowel disease Series A-2 led by Hatteras Venture Partners and Biohaven Donnie McGrath, M.D., and Seth Rudnick, M.D., join Artizan’s board of directors NEW HAVEN, Conn., March 01, 2021 (GLOBE NEWSWIRE) -- Artizan Biosciences, Inc. (“Artizan”), a biotechnology company focused on addressing inflammatory diseases involving the human intestinal microbiota, today announced the company...
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) delivered earnings and revenue surprises of -25.26% and 0.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Biohaven Pharmaceutical (NYSE:BHVN) decreased 0.1% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 5.61% year over year to ($2.69), which beat the estimate of ($2.97). Revenue of $35,114,000 up by 0.00% year over year, which beat the estimate of $28,230,000. Looking Ahead Earnings guidance hasn't been issued by the company for now. Biohaven Pharmaceutical hasn't issued any revenue guidance for the time being. Details Of The Call...
Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and full year 2020 and provided a review of recent accomplishments and anticipated upcoming milestones.
NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Biohaven Pharmaceutical Holding Co. (NYSE:BHVN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 1, 2021 at 8:30 AM Eastern Time.